L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial

NCT00549575 Phase 3 TERMINATED

Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).

Details

Lead sponsor	Nantes University Hospital
Phase	Phase 3
Status	TERMINATED
Enrolment	44
Start date	2000-07
Completion	2006-06

Conditions

• Intra Uterine Growth Retardation

Interventions

• L ARG
• Placebo

Primary outcomes

• The principal outcome is birth weight at delivery and neonatal morbidity (Crib Score) — 6 weeks

Countries

France